PRESS RELEASE
2 February 2026

Elliott Gold Discusses The "Not Inherently Distinctive” (NID) Objection In IPHQ News

SB
Smart & Biggar

Contributor

Smart & Biggar uncovers and maximizes intellectual property and technology assets for our clients. Today’s fast-paced innovation economy demands a higher level of expertise and attention to detail when it comes to IP strategy and protection. With over 125 lawyers, patent agents and trademark agents collaborating across five Canadian offices, Smart & Biggar is trusted by the world’s leading innovators to find value in their IP rights. As market leaders in IP, Smart & Biggar’s team is on the pulse when it comes to the latest developments and the wider industry changes that impact our clients. To stay informed, visit smartbiggar.ca/insights, including access to our RxIP Update (smartbiggar.ca/insights/rx-ip-updates), a monthly digest of the latest decisions and law surrounding the life sciences and pharmaceutical industries.
The 2019 introduction of the “not inherently distinctive” (NID) objection to trademark (TM) registration to the Canada Trademarks Act...
Canada

The 2019 introduction of the “not inherently distinctive” (NID) objection to trademark (TM) registration to the Canada Trademarks Act has presented a challenge for trademark registration applicants and practitioners alike.

“The NID objection is seen as a unique barrier to doing business in Canada.”

– Elliott Gold

Read the full article on IPHQ News, the IP news and insights platform of IPH Limited: Coping with the “Not Inherently Distinctive” Objection in the Canada Trademarks Act

Contributor

Smart & Biggar uncovers and maximizes intellectual property and technology assets for our clients. Today’s fast-paced innovation economy demands a higher level of expertise and attention to detail when it comes to IP strategy and protection. With over 125 lawyers, patent agents and trademark agents collaborating across five Canadian offices, Smart & Biggar is trusted by the world’s leading innovators to find value in their IP rights. As market leaders in IP, Smart & Biggar’s team is on the pulse when it comes to the latest developments and the wider industry changes that impact our clients. To stay informed, visit smartbiggar.ca/insights, including access to our RxIP Update (smartbiggar.ca/insights/rx-ip-updates), a monthly digest of the latest decisions and law surrounding the life sciences and pharmaceutical industries.

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More